SOPHiA Genetics SA Profit Margin

SOPHiA Genetics SA (SOPH) currently reports a profit margin of -99.7% as of March 2026. That compares with -98.51% in the prior-year period — down 1.2% year over year. That is below the Healthcare sector average of 14.34%. Use the charts on this page to explore SOPHiA Genetics SA's profit margin history and peer comparisons.

SOPHiA Genetics SA's profit margin decreased from -98.51% to -99.7% — a 1.2% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

SOPHiA Genetics SA's profit margin of -99.7% is lower than the Healthcare sector average of 14.34%. That is roughly 795.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but SOPHiA Genetics SA's current -99.7% should be judged against Healthcare norms (sector average: 14.34%) and against SOPH's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -99.7%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.34%. From there, open related valuation or income-statement pages for SOPHiA Genetics SA, and consider following SOPH for alerts when major investors trade the stock.